Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review (original) (raw)

Antifungal drug dosing adjustment in critical patients with invasive fungal infections

Athina Pyrpasopoulou

Journal of Emergency and Critical Care Medicine

View PDFchevron_right

Choosing the Right Antifungal Agent in ICU Patients

nadim CASSIR

Advances in Therapy

View PDFchevron_right

Choice of initial antifungal therapy in critically Ill patients

sudha madhavan

International Journal of Health Sciences (IJHS), 2022

View PDFchevron_right

Timely selection of adequate antifungal therapy for candidemia in the critically ill: Donʼt let the yeast rise!*

Alberto Corona

Critical Care Medicine, 2008

View PDFchevron_right

Systemic antifungal therapy in critically ill patients without invasive fungal infection*

Hervé Dupont

Critical Care Medicine, 2012

View PDFchevron_right

Antifungal Dose Adjustment in Renal and Hepatic Dysfunction: Pharmacokinetic and Pharmacodynamic Considerations

David Burgess

Current Fungal Infection Reports, 2010

View PDFchevron_right

Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy

Pankaj Jorwal

Revista iberoamericana de micología, 2006

View PDFchevron_right

Antifungal agents for invasive candidiasis in non-neutropenic critically ill adults: What do the guidelines recommend?

M. Van Driel

International Journal of Infectious Diseases, 2019

View PDFchevron_right

Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data

Philippe Montravers

Intensive Care Medicine, 2015

View PDFchevron_right

Incidence of candidaemia and antifungal sensitivity in critically ill patients

Vincenzo Vullo, Maria Mascellino

View PDFchevron_right

Susceptibility profiles and clinical efficacy of antifungals against candida bloodstream isolates from critically ill patients: Focus on intravenous itraconazole

Chrisostomos Katsenos

International Journal of Antimicrobial Agents, 2019

View PDFchevron_right

Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders

David Kong

Internal Medicine Journal, 2008

View PDFchevron_right

Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Dominique Sanglard

Intensive Care Medicine, 2014

View PDFchevron_right

Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside

George Drusano

Clinical Microbiology and Infection, 2009

View PDFchevron_right

Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections

Eleonora Swart

Antimicrobial Agents and Chemotherapy, 2017

View PDFchevron_right

Are prophylactic antifungals in highly colonized patients safe and effective?

Cristóbal León

Intensive Care Medicine, 2015

View PDFchevron_right

Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration

J. Belda

International journal of antimicrobial agents, 2017

View PDFchevron_right

A bedside scoring system (???Candida score???) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization

Pedro Saavedra

Critical Care Medicine, 2006

View PDFchevron_right

Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients

J. Kosterink

Antimicrobial Agents and Chemotherapy, 2021

View PDFchevron_right

Management of candidiasis Management of Candida species infections in critically ill patients

Jorge Garbino

The Lancet Infectious Diseases, 2003

View PDFchevron_right

Empirical treatment of candidemia in intensive care units: Fluconazole or broad-spectrum antifungal agents?

Teresa Peláez

Medical Mycology, 2009

View PDFchevron_right

Antifungals patterns in critical patients with candidiasis in the intensive care units at Sanglah General Hospital 2019

Ady Widayana

Neurologico Spinale Medico Chirurgico, 2019

View PDFchevron_right

Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials

massimo attanasio

Journal of Antimicrobial Chemotherapy, 2006

View PDFchevron_right

Invasive Candida Infections and the Harm From Antibacterial Drugs in Critically Ill Patients

Morten Bestle

Critical Care Medicine, 2015

View PDFchevron_right

How to treat fungal infections in ICU patients

Dimitrios Matthaiou

BMC Infectious Diseases, 2015

View PDFchevron_right

Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study

Jesús Gomez

Critical care medicine, 2017

View PDFchevron_right

Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy

Andreas Groll

Drugs, 2004

View PDFchevron_right

Invasive Fungal Infections in Critically Ill Patients

Armin Ahmed

2016

View PDFchevron_right

Double-Blind Placebo-Controlled Trial of Fluconazole to Prevent Candidal Infections in Critically Ill Surgical Patients

Marie Diener-West

Annals of Surgery, 2001

View PDFchevron_right

Hospital use of systemic antifungal drugs

Frank Dörje

BMC clinical pharmacology, 2005

View PDFchevron_right

(1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study

Maria Sole Vallecoccia

Journal of Antimicrobial Chemotherapy, 2016

View PDFchevron_right

Single-drug therapy or selective decontamination of the digestive tract as antifungal prophylaxis in critically ill patients: a systematic review

Johannes Reitsma

Critical Care, 2007

View PDFchevron_right